Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease

Journal of Neuroinflammation

Volumn 6, Issue , 2009, Pages 22-

  Combarros, Onofre ^a   van Duijn, Cornelia M ^b   Hammond, Naomi ^c   Belbin, Olivia ^d   Arias Vásquez, Alejandro ^b   Cortina Borja, Mario ^e   Lehmann, Michael G ^f   Aulchenko, Yurii S ^b   Schuur, Maaike ^b   Kölsch, Heike ^g   Heun, Reinhard ^g,h   Wilcock, Gordon K ^i,j   Brown, Kristelle ^d   Kehoe, Patrick G ^j   Harrison, Rachel ^j   Coto, Eliecer ^k   Alvarez, Victoria ^k   Deloukas, Panos ^c   Mateo, Ignacio ^a   Gwilliam, Rhian ^c   Morgan, Kevin ^d   Warden, Donald R ^f   Smith, A David ^f   Lehmann, Donald J ^f   more..

^a UNIVERSITY OF CANTABRIA   (Spain)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF BONN   (Germany)

^h DERBY CITY GENERAL HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j UNIVERSITY OF BRISTOL   (United Kingdom)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CYTOSINE; DNA; GUANINE; INTERLEUKIN 10; INTERLEUKIN 6; TYROSINE;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; EPISTASIS; EUROPE; FEMALE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PATHOGENESIS; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; BRAIN CHEMISTRY; DNA MUTATIONAL ANALYSIS; ENCEPHALITIS; EPISTASIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 71049194220     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-6-22     Document Type: Article

References (66)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421. 10.1016/S0197-4580(00)00124-X, 10858586.
2. Rogers J, Webster S, Lue L-F, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996, 17:681-686. 10.1016/0197-4580(96)00115-7, 8892340.
3. Gruol DL, Nelson TE. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997, 15:307-339. 10.1007/BF02740665, 9457704.
4. Strle K, Zhou JH, Shen W-H, Broussard SR, Johnson RW, Freund GG, Dantzer R, Kelley KW. Interleukin-10 in the brain. Crit Rev Immunol 2001, 21:427-449.
5. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the Alzgene database. Nature Genetics 2007, 39:17-23. Accessed on 14 July, 2009., 10.1038/ng1934, 17192785.
6. Moore JH, Williams SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. BioEssays 2005, 27:637-646. 10.1002/bies.20236, 15892116.
7. Wade MJ. Epistasis, complex traits, and mapping genes. Genetica 2001, 112-113:59-69. 10.1023/A:1013316611768, 11838787.
8. Infante J, Sanz C, Fernández-Luna JL, Llorca J, Berciano J, Combarros O. Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology 2004, 63:1135-1136.
9. Bergem ALM, Engedal K, Kringlen E. The role of heredity in late-onset Alzheimer disease and vascular dementia - a twin study. Arch Gen Psychiatry 1997, 54(3):264-270.
10. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ. The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes 2009, 2(1):105. 10.1186/1756-0500-2-105, 2706251, 19527493.
11. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984, 34:939-944.
13. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ. Epistasis in sporadic Alzheimer's disease. Neurobiol Aging 2009, 30:1333-1349. 10.1016/j.neurobiolaging.2007.11.027, 18206267.
14. Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int 2007, 50:12-38. 10.1016/j.neuint.2006.07.007, 16973241.
15. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356. 10.1126/science.1072994, 12130773.
16. Perry G, Nunomura A, Hirai K, Zhu X, Pérez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Rad Biol Med 2002, 33:1475-1479. 10.1016/S0891-5849(02)01113-9, 12446204.
17. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia. Arch Neurol 2009, 66:300-305. 10.1001/archneurol.2009.27, 19273747.
18. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine?. Food Nutr Bull 2008, 29:S143-S172.
19. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, Debette S, Lumley T, Folsom AR, van den Herik EG. Genomewide association studies of stroke. N Engl J Med 2009, 360:1718-1728. 10.1056/NEJMoa0900094, 19369658.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
21. Armitage P. Statistical Methods in Medical Research. 1983, Oxford: Blackwell Scientific Publications.
22. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993, 41:176-181.
23. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 1994, 15:771-772. 10.1016/0197-4580(94)90066-3, 7534383.
24. Young DG, Skibinski G, Mason JI, James K. The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor β1 (TGF-β1) levels in normal healthy blood donors. Clin Exp Immunol 1999, 117:476-481. 10.1046/j.1365-2249.1999.01003.x, 1905380, 10469050.
25. Weaver JD, Huang M-H, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline. Neurology 2002, 59:371-378.
26. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76-80.
27. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005, 64:1371-1377.
28. Cohen HJ, Harris T, Peiper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003, 114:180-187. 10.1016/S0002-9343(02)01484-5, 12637131.
29. Harris TB, Ferrucci L, Tracy RP, Corti M-C, Wacholder S, Ettinger WHJ, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512. 10.1016/S0002-9343(99)00066-2, 10335721.
30. Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, Seeman TE. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 2002, 50:638-644. 10.1046/j.1532-5415.2002.50157.x, 11982663.
31. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women's Health and Aging Study. Circulation 2001, 103:947-953.
32. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322. 10.1161/01.CIR.0000097109.90783.FC, 14568895.
33. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB, Pahor M. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] study). Am J Cardiol 2003, 92:522-528. 10.1016/S0002-9149(03)00718-5, 12943870.
34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
35. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334. 10.1001/jama.286.3.327, 11466099.
36. Testa R, Olivieri F, Bonfigli AR, Sirolla C, Boemi M, Marchegiani F, Marra M, Cenerelli S, Antonicelli R, Dolci A. Interleukin-6-174G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 71:299-305. 10.1016/j.diabres.2005.07.007, 16140413.
37. Kiecolt-Glaser JK, Preacher KJ, MacCullum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003, 100:9090-9095. 10.1073/pnas.1531903100, 166443, 12840146.
38. Castellanos M, Castillo J, García MM, Leira R, Serena J, Chamorro A, Dávalos A. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002, 33:982-987. 10.1161/hs0402.105339, 11935048.
39. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, Tarkowski A. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995, 26:1393-1398.
40. Baranowska-Bik A, Bik W, Wolinska-Witort E, Martynska L, Chmielowska M, Barcikowska M, Baranowska B. Plasma β amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett 2008, 29:75-79.
41. Bermejo P, Martín-Aragón S, Benedí J, Susín C, Felici E, Gil P, Ribera JM, Villar T. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008, 117:198-202. 10.1016/j.imlet.2008.02.002, 18367253.
42. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LME. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J Neuroimmunol 2000, 103:97-102. 10.1016/S0165-5728(99)00226-X, 10674995.
43. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol 2004, 61:668-672. 10.1001/archneur.61.5.668, 15148142.
44. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C. Blood inflammatory markers and risk of dementia: the Conselice Study of Brain Aging. Neurobiol Aging 2007, 28:1810-1820. 10.1016/j.neurobiolaging.2006.08.012, 17011077.
45. van Duijn CM, Hofman A, Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci Lett 1990, 108:350-354. 10.1016/0304-3940(90)90666-W, 2304653.
46. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991, 285:111-114. 10.1016/0014-5793(91)80737-N, 1712317.
47. Hampel H, Haslinger A, Scheloske M, Padberg F, Fischer P, Unger J, Teipel SJ, Neumann M, Rosenberg C, Oshida R. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur Arch Psychiatry Clin Neurosci 2005, 255:269-278. 10.1007/s00406-004-0558-2, 15565298.
48. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000, 57:1153-1160. 10.1001/archneur.57.8.1153, 10927795.
49. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, Quirion R. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 1993, 629:245-252. 10.1016/0006-8993(93)91327-O, 7509248.
50. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 1998, 12:215-227. 10.1097/00002093-199809000-00016, 9772027.
51. Heyen JR, Ye S, Finck BN, Johnson RW. Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NFκ B. Brain Res Mol Brain Res 2000, 77:138-147. 10.1016/S0169-328X(00)00042-5, 10814840.
52. Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate Aβ (1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol 2001, 113:49-62. 10.1016/S0165-5728(00)00404-5, 11137576.
53. Sawada M, Suzumura A, Hosoya H, Marunouchi T, Nagatsu T. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem 1999, 72:1466-1471. 10.1046/j.1471-4159.1999.721466.x, 10098850.
54. Posthuma D, Meulenbelt I, de Craen AJM, de Geus EJC, Slagboom PE, Boomsma DI, Westendorp RGJ. Human cytokine response to ex vivo amyloid-β stimulation is mediated by genetic factors. Twin Res Hum Genet 2005, 8:132-137.
55. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376. 10.1172/JCI2629, 508984, 9769329.
56. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000, 275:18138-18144. 10.1074/jbc.M000379200, 10747905.
57. Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 2004, 53(8):1082-1089. 10.1136/gut.2003.029736, 1774164, 15247172.
58. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999, 42:1101-1108. 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y, 10366102.
59. Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K, Mathieson PW. The interleukin-10 -1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 2002, 59:560-569. 10.1007/s00018-002-8448-0, 11964134.
60. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors - a twin study. Genes Immun 2002, 3:407-413. 10.1038/sj.gene.6363920, 12424622.
61. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNFα, LT α l and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000, 1:185-190. 10.1038/sj.gene.6363657, 11196710.
62. Suárez A, Castro P, Alonso R, Mozo L, Gutiérrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003, 75:711-717. 10.1097/01.TP.0000055216.19866.9A, 12640314.
63. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
64. Yilmaz V, Yentür SP, Saruhan-Direskeneli G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine 2005, 30:188-194. 10.1016/j.cyto.2005.01.006, 15863393.
65. Huizinga TWJ, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, Pitzalis C, Drossaers-Bakker WK, Westendorp RGJ, Breedveld FC. Are differences in interleukin 10 production associated with joint damage?. Rheumatology 2000, 39:1180-1188. 10.1093/rheumatology/39.11.1180, 11085795.
66. Warlé MC, Farhan A, Metselaar HJ, Hop WCJ, Perrey C, Zondervan PE, Kap M, Kwekkeboom J, Ijzermans JNM, Tilanus HW. Are cytokine gene polymorphisms related to in vitro cytokine production profiles?. Liver Transpl 2003, 9:170-181. 10.1053/jlts.2002.50014, 12548511.